Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
23andMe Holding Co. - Common Stock
(NQ:
ME
)
0.6063
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 23andMe Holding Co. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
March 09, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
March 02, 2023
There's nothing better than getting a bargain that'll pay off for years.
Via
The Motley Fool
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
February 28, 2023
Both are likely to double quite soon, and they aren't even that risky.
Via
The Motley Fool
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and...
From
23andMe Holding Co.
Via
GlobeNewswire
This Genetics Stock Could Have Massive Long-Term Potential
February 10, 2023
This healthcare company isn't without risk but is doing a good job executing on its vision.
Via
The Motley Fool
A Preview Of 23andMe Holding's Earnings
February 07, 2023
Via
Benzinga
23andMe to Present at Upcoming Investor Conferences
February 22, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 09, 2023
Gainers Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday.
Via
Benzinga
MGM Resorts, Madison Square Garden Entertainment, Cardiovascular Systems And Other Big Stocks Moving Higher On Thursday
February 09, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 08, 2023
Via
Benzinga
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
7 Former SPACs I Still Own (And What I Think Now)
January 28, 2023
Remember the SPAC boom? Here are seven products of that time that are still in my portfolio.
Via
The Motley Fool
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
3 Penny Stocks That Could Make You Filthy Rich
January 25, 2023
These low-priced equities could deliver enormous returns for risk-tolerant shareholders.
Via
The Motley Fool
My 4 Worst-Performing Stocks and What I Think Now
January 10, 2023
These stocks are all down 70% or more from what I paid.
Via
The Motley Fool
Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
December 16, 2022
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
25 Meme Stocks to Sell Before They Die
December 15, 2022
Wondering what the best meme stocks to sell for 2023 are? Here are the top picks that investors should offload and avoid.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Friday
January 06, 2023
During Friday's trading, 71 companies set new 52-week lows.
Via
Benzinga
The Worst Investment Decision I Made in 2022
December 10, 2022
The stock market has had a terrible year, and here are some moves we wish we could do over.
Via
The Motley Fool
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 05, 2023
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
November 29, 2022
Via
Benzinga
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 10, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
TheNewswire.com
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 09, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
Benzinga
23andMe Reports FY2023 Second Quarter Financial Results
November 07, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07, 2022
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity
From
23andMe Holding Co.
Via
GlobeNewswire
A Preview Of 23andMe Holding's Earnings
November 04, 2022
23andMe Holding (NASDAQ:ME) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that 23andMe Holding...
Via
Benzinga
I Bought 2 SPACs That Haven't Lived Up to Expectations -- Here's Why I'm Still Holding Them
October 28, 2022
These companies haven't performed as well as I thought they would, but I don't plan to sell.
Via
The Motley Fool
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
October 27, 2022
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for...
From
23andMe Holding Co.
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.